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Abstract
Background: Whole genome amplification (WGA) offers new possibilities for genome-wide
association studies where limited DNA samples have been collected. This study provides a realistic
and high-precision assessment of WGA DNA genotyping performance from 20-year old archived
serum samples using the Affymetrix Genome-Wide Human SNP Array 6.0 (SNP6.0) platform.
Results: Whole-genome amplified (WGA) DNA samples from 45 archived serum replicates and
5 fresh sera paired with non-amplified genomic DNA were genotyped in duplicate. All genotyped
samples passed the imposed QC thresholds for quantity and quality. In general, WGA serum DNA
samples produced low call rates (45.00 +/- 2.69%), although reproducibility for successfully called
markers was favorable (concordance = 95.61 +/- 4.39%). Heterozygote dropouts explained the
majority (>85% in technical replicates, 50% in paired genomic/serum samples) of discordant results.
Genotyping performance on WGA serum DNA samples was improved by implementation of
Corrected Robust Linear Model with Maximum Likelihood Classification (CRLMM) algorithm but
at the loss of many samples which failed to pass its quality threshold. Poor genotype clustering was
evident in the samples that failed the CRLMM confidence threshold.
Conclusions: We conclude that while it is possible to extract genomic DNA and subsequently
perform whole-genome amplification from archived serum samples, WGA serum DNA did not
perform well and appeared unsuitable for high-resolution genotyping on these arrays.
Background
Array technologies are designed to rapidly genotype hun-
dreds of thousands of single nucleotide polymorphisms
(SNPs) across the genome using a relatively small amount
of DNA. Advances in genotyping platforms have allowed
cost-effective, whole-genome scans of multiple individu-
als in large-scale association studies. These studies are
aimed at identifying genetic factors affecting many impor-
tant complex human diseases. DNA samples from care-
fully characterized populations that are necessary to carry
out adequately powered genome-wide association studies
(GWAS), however, are often limiting. Collecting a suffi-
cient number of appropriate samples for GWAS can be a
complex and expensive collaborative challenge. There are
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potential alternative sources of genomic DNA for which
important medical phenotypes have been recorded but
their utility for GWAS has been poorly explored.
Archiving of serum samples is widely practiced in research
and clinical domains [1]. Records of phenotype informa-
tion associated with individual serum samples may be val-
uable for the GWAS setting. Archived serum samples are,
therefore, an attractive and convenient potential source of
genomic DNA. As an obstacle to genotyping, limited DNA
yield could be overcome by taking advantage of recent
whole-genome amplification (WGA) technologies [2-8].
Multiple displacement amplification (MDA), in particu-
lar, is an improved WGA technology known to minimize
amplification bias, incomplete genome coverage, and
generation of relatively short fragments. MDA utilizes a
highly processive ϕ29 DNA polymerase and a mix of ran-
dom hexamer primers and is capable of amplifying par-
tially degraded and low quantity DNA sources. Reliable
MDA-based whole-genome amplification of DNA from
serum samples has been demonstrated [9]. Previous stud-
ies have successfully utilized WGA DNA from archived
sera on a relatively small number of SNP markers using
single assay methods [10-12]. A recent study by Mead et al
showed that WGA serum DNA could be used for custom
targeted medium-throughput genotyping[13]. Neverthe-
less, an unbiased genome wide scan with SNP markers
using residual DNA in archived serum specimens will
require the use of high throughput array-based genotyp-
ing. It is, therefore, necessary to determine whether this is
technically feasible with standard technologies that are
currently available for GWAS.
In this study, we describe a large and statistically robust
study of genotyping WGA serum DNA on a widely-used
whole genome SNP-genotyping panel. The Genome-Wide
Human SNP Array 6.0 features about 1.8 million genetic
markers, including assays for more than 906,600 single
nucleotide polymorphisms (SNPs) and 946,600 probes
for detection of copy number variation[14]. We further
compare the performance of two different genotype-call-
ing algorithms that are compatible with SNP 6.0 genotyp-
ing array (Birdseedv.2.0 and CRLMM). Compared to
previous studies, the results of our work provide more pre-
cise and accurate estimates of genotyping efficiency and
error rates using WGA serum DNA. Establishing archived
serum samples as a reliable, alternative DNA source may
boost the power of large-scale GWAS particularly in cases
where available DNA samples from suitable subjects are
limited.
Results
Quality control for WGA serum DNA SNP 6.0 genotyping
We successfully isolated genomic DNA from 100% of sev-
enty-five, 20-year old 500 uL frozen serum samples using
the Qiagen DNA Mini Kit (Qiagen, CA). The yield of
genomic DNA ranged from 31.5 ng to 608.4 ng (mean +/
- SD, 202.7 +/- 122.3 ng). Purified DNA samples were
then whole-genome amplified via multiple displacement
amplification (MDA). MDA was the method of choice for
WGA in this study because our pilot studies using Affyme-
trix TG array demonstrated superior genotyping results
from MDA-amplified serum DNA compared to samples
amplified via other WGA methods (results not shown).
Furthermore, Affymetrix recommends the use of Repli-G
for their genotyping chemistry. We avoided the use of
WGA methods which includes random fragmentation of
DNA target because >200 bp fragment lengths must be
amplified when using SNP 6.0 genotyping arrays. In this
study, WGA of serum DNA samples by MDA resulted in
5500-fold to 65000-fold amplification relative to input
DNA. Our yields for WGA DNA ranged from 30800 ng to
125900 ng (mean +/- SD, 18536 +/- 11754 ng). To reduce
genotyping error associated directly with variation in the
WGA [15,16], the 40 top-yielding samples were carried
over to the genotyping process. All samples passed to the
genotyping step produced relatively uniform quantity and
quality of DNA (purification yield of 229 +/- 136 ng;
whole-genome amplification yield of 84409 +/- 6086 ng;
moderate to intense amplified PCR bands, and intact 10
kb fraction in 1% agarose gel). Two aliquots were taken
from each DNA preparation for WGA and were genotyped
as technical replicates. All WGA DNA were successfully
run on the SNP 6.0 array, with the exception of 1 technical
replicate sample. However, quality control (QC) call rates
of WGA serum DNA samples ranged from 49.2% to
95.6% (mean +/- SD, 67.1 +/- 10.1%) when analyzed by
the standard Birdseed algorithm[17]. WGA serum DNA
performance based on the SNP6.0 QC call rates showed
poor correlation with yield after DNA purification (r2 =
0.122), WGA yield (r2 = 0.164) and intensity of 60 bp
PCR-amplified band (r2 = 0.001).
Call rates
To evaluate SNP 6.0 array genotyping efficiency on WGA
serum DNA samples, we measured the proportion of
SNPs with missing calls in the genotyped samples.
Genomic DNA from peripheral whole blood paired with
whole-genome amplified DNA from freshly isolated
serum of 5 individuals were run on SNP 6.0 arrays as con-
trols. Genotype data were inferred by implementing the
Birdseed v2.0 algorithm at 0.1 confidence threshold in
separate clusters of non-amplified and WGA DNA sam-
ples (see Additional File 1 and Additional File 2). Percent
call rates from WGA serum DNA and genomic DNA are
shown in Figure 1. Overall, WGA DNA samples from sera
yielded significantly low call rates (mean +/- SD, 45.0 +/-
2.7%), which corresponded to 409,366 markers out of
approximately 906,600 SNP markers represented on the
SNP 6.0 array. In contrast to WGA serum DNA samples,BMC Genetics 2009, 10:85 http://www.biomedcentral.com/1471-2156/10/85
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non-amplified DNA samples from peripheral whole
blood yielded excellent call rates, ranging from 96.9% to
99.5% (mean +/- SD, 98.0 +/- 1.1%). The average call rate
of WGA DNA samples from archived sera (mean +/- SD,
44.6 +/2.7%) did not differ from WGA DNA samples from
freshly isolated sera (mean +/- SD, 48.1 +/- 1.8%) (p = 6
× 10-5 ). Call rates between technical replicates were corre-
lated (r2 = 0.71), thus demonstrating that high quality
serum DNA samples consistently produce high genotyp-
ing call rates compared to samples with poor quality
DNA(Figure 2).
Genotype concordance between technical replicates
We further evaluated the quality of SNP 6.0 genotyping
performance on WGA serum DNA samples by measuring
the repeatability of calls between technical replicates as
shown in Figure 3 (see Additional File 3). Reports for con-
cordance were restricted to SNP loci with complete geno-
type calls on both technical replicates of a given
individual. Genotype data between technical replicates
gave modest percent concordances, ranging from 77.3 to
99.9 (mean +/- SD, 95.2 +/- 4.6) over approximately
340,000 SNP loci. We then determined the percent contri-
bution of allele switch (AA ←→ BB) or heterozygote drop-
out (AB → AA or BB) to the observed global discordance
as shown in Figure 3 (see Additional File 4). In all techni-
cal samples, discordance occurred largely due to heterozy-
gote dropout, with an average of 85.9%. Allele switch was
less common and contributed to 14.1% of the global dis-
cordance.
Genotype concordance between paired samples
In order to assess whether accurate genotypes can be
obtained from WGA serum DNA using SNP 6.0 arrays, we
examined the fidelity of WGA serum DNA genotypes to
their corresponding non-amplified DNA genotypes (Table
1). Calculation of concordance was restricted to SNPs
where calls are made on both samples of a pair. Unlike
technical replicates, paired samples showed gross discord-
ances that ranged from 17.77% to 44.25% of the average
282,256 called markers (mean +/- SD, 31.03 +/- 12.05%).
In all paired samples, the majority of discordant markers
were caused by heterozygote dropout (AB→AA or BB), with
an average of 50%. Of the observed heterozyogote drop-
outs, 69.3% were due to conversion of purine to another
purine or pyrimidine to another pyrimidine. In contrast,
other genotyping errors such as allele switch (AA←→BB)
and heterozygote gain (AA or BB → AB) contributed an
only average of 16.9% and 33.2%, respectively, to global
discordance (Table 2). The genotype concordance (repro-
ducibility) for identical samples using the SNP6.0 microar-
Relative call rates between archived samples and controls Figure 1
Relative call rates between archived samples and 
controls. Average genotype call rates from Birdseedv2.0 
analysis at a default confidence threshold of 0.1 showed rela-
tive performance of genotyped samples on SNP 6.0 platform.
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Performance analysis of technical replicate samples.
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ray is expected to exceed 99.9% (Affymetrix
data sheet: http://www.affymetrix.com/support/technical/
datasheetgenomewide_snp6_datasheet.pdf.
Performance Comparison of Genotype Calling Algorithms
Previous studies have shown that genotype calling algo-
rithms show variable performance in normalization and
clustering [18]. We sought to determine whether a differ-
ent clustering algorithm would improve the repeatability
and accuracy of genotype inference when WGA serum
DNA samples were used. Genotypes of technical replicates
and paired samples were inferred using CRLMM (Cor-
rected Robust Linear Model with Maximum Likelihood
Classification) algorithm from separate signal intensity
clusters of non-amplified and WGA DNA samples at
0.999 confidence threshold (see Additional File 5, Addi-
tional File 6, Additional File 7 and Additional File 8).
Overall, CRLMM showed improved genotype perform-
ance in comparison to Birdseed v2.0 (Figure 4). In con-
trast to the Birdseedv2.0 algorithm, CRLMM yielded
higher call rates for WGA serum DNA (mean +/- SD,
663320 +/- 134762 markers). Higher concordances
between technical replicates were also observed, ranging
from 99.77% to 99.93% (mean +/- SD, 99.87 +/- 0.001)
over an average of 542,538 markers. However, CRLMM
exhibited very low tolerance to poor quality samples,
showing 78.75% sample rejection rate. Similar to the
Birdseed v2.0, CRLMM showed gross discordance
between non-amplified genomic DNA and corresponding
WGA serum DNA (mean +/- SD, 36.39 +/- 6.98).
Chip Quality Measures as Sample Rejection Determinants
To investigate the basis for sample rejection by CRLMM,
we visually assessed the chip quality of WGA samples. Sig-
nal intensities from probe A (Theta A) and probe B (Theta
B) of SNPs assayed on SNP6.0 platform were plotted to
capture the extent of differences between the intensity val-
ues AA, AB and BB genotypes. In figure 5, we show that
sample performance correlated well with the separation of
genotype clusters on the chip of a given sample. Geno-
typed samples with high confidence values and high call
rates, such as genomic DNA (Figure 5a) or a representative
successful WGA serum DNA (Figure 5b), showed three
distinct clusters, corresponding to the three genotypes. On
the other hand, very poor separation of clusters is the hall-
mark of the poor-performing and rejected WGA DNA
samples (Figure 5c).
Effects of Amplicon Fragment Length on Individual Marker 
Performance
We next determined whether amplicon fragment length
affect genotype concordance and marker genotyping effi-
ciency. As a measure of marker genotyping efficiency, we
computed the average confidence values and concordance
Table 1: Genotype concordance between paired samples.
Paired Sample ID Total Genotype Calls* %Concordance** %Discordance
INF001 414541 55.75% 44.25%
INF002 419350 67.87% 32.13%
INF003 424260 58.86% 41.14%
INF004 453353 81.98% 18.02%
INF005 453512 82.23% 17.77%
MEAN 430994 68.97% 31.03%
*Number of markers with calls between paired samples
**%Concordance is the proportion of markers with consistent genotype calls in a paired sample.
Table 2: Analysis of global genotyping error in WGA serum DNA samples.
Paired Sample ID* Allele Switch** (AA←→BB) Heterozygote Gain**(AA or 
BB→AB)
Heterozygote Dropout**(AB→BB or 
AA)
INF001 25.8% 30.0% 44.2%
INF002 18.5% 40.5% 41.0%
INF003 23.6% 25.3% 51.1%
INF004 9.9% 32.0% 58.2%
INF005 6.6% 38.0% 55.5%
MEAN 16.9 33.2% 50.0%
*Genotype calls between a paired sample (non-amplified genomic DNA vs WGA serum DNA) were compared.
**Percentages are based on the total number of discordant markers or markers with mismatched genotype calls in paired samplesBMC Genetics 2009, 10:85 http://www.biomedcentral.com/1471-2156/10/85
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rates for each marker. Good markers were consistently
called at a high confidence level across samples, and there-
fore produced high average confidence values regardless
of amplicon fragment length (see Additional File 9).
Moreover, good markers exhibited high concordance rates
across all WGA serum DNA regardless of amplicon frag-
ment length (see Additional File 10). The correlation of
average confidence values against amplicon fragment
length or genotype concordance was 0.007 and 0.016,
respectively.
Discussion
Our data show that DNA from archived serum samples
cannot substitute for good quality genomic DNA using
the standard technologies employed in this study. In our
effort to establish serum as an alternative DNA source for
future large-scale GWAS, we have extensively tested the
performance of WGA DNA recovered from sera of 40
twenty-year old archived samples on the SNP 6.0 plat-
form. Large standard deviations in DNA yield during the
early stage of DNA preparation suggested that DNA from
archived serum samples were variably prone to degrada-
tion. Selection of WGA DNA samples with uniform yield
and quality did little to improve genotyping performance.
Of note, all WGA DNA from serum samples in the study
gave call rates of less than half of the total markers assayed
on SNP 6.0 platform, far below the call rates of our non-
amplified genomic DNA controls (mean +/- SD, 98.03 +/
- 1.05%). More importantly, genotypes of WGA DNA
from serum samples and their non-amplified DNA coun-
Birdseedv2.0 vs CRLMM SNP 6.0 genotyping performance on  WGA samples Figure 4
Birdseedv2.0 vs CRLMM SNP 6.0 genotyping per-
formance on WGA samples. Assessment of genotype 
calling performance of Birdseed v2.0 and CRLMM algorithms 
from WGA DNA from serum samples on SNP6.0 genotyping 
platform is shown by comparison of (a) call rates (b) con-
cordance between technical replicates and (c) paired sample 
concordance.
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Chip quality assessment of good performing sample vs bad  performing sample on SNP 6.0 genotyping platform Figure 5
Chip quality assessment of good performing sample 
vs bad performing sample on SNP 6.0 genotyping 
platform. Scattergram plots of probe intensity values for 
allele B (Theta B) against allele A (Theta B) were generated 
from arrays of a (a) non-amplified genomic DNA sample, (b) 
good performing WGA DNA from serum and (c) bad per-
forming WGA DNA from serum. Each point in the plot rep-
resents an assayed marker on the SNP 6.0 platform. Dark 
areas in the plot represent space with high-density points 
whereas light areas represent space with low-density points.BMC Genetics 2009, 10:85 http://www.biomedcentral.com/1471-2156/10/85
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terpart showed gross mismatches affecting 80-300,000
markers out of ~430,000 total called markers. For samples
in which non-amplified genomic DNA were available, the
relative proportion of mismatches as reflected by %dis-
cordance was consistent between paired samples (Table
1) and their corresponding technical replicates (see Addi-
tional File 3). For example, the best performing sample
(INF002) consistently produced the least %discordance in
both paired sample and technical replicate compared to
other samples. Our data altogether suggest that the quality
of DNA that can be extracted from archived serum sam-
ples is inherently very poor. This factor alone accounted
for the vast majority of genotyping failure in this study.
We further studied possible sources of inaccurate geno-
types. Heterozygote dropout was the most common error
detected in discordant assays in both technical replicates
(85%) and paired samples (50%). This suggests that DNA
in archived serum samples were prone to allele bias dur-
ing WGA. Allele switch in genotypes of technical replicates
may have arisen from generation of amplification error
during WGA stage although poor genotype calling is the
more likely explanation. This accounted for <15% dis-
cordances in technical replicates and 16.9% in paired
samples of the discordant genotypes. Lower than average
probe signal intensities (Figure 5c), which resulted in loss
of genotype information or heterozygote gain (33% dis-
cordant markers in paired samples), may have been
caused by inefficient amplification during WGA due to
the variable presence of highly degraded DNA fragments
in the serum samples. Such errors in WGA were previously
reported particularly when suboptimal DNA sources were
used [2,9,12,13,19]. However, poor correlation between
probe performance across samples and lengths of ampli-
fied fragments on the SNP 6.0 platform suggest that the
poor genotyping results from WGA serum DNA cannot be
explained simply by DNA degradation (see Additional
File 9 and Additional File 10). Indeed, genotypes were
called and high concordance rates were observed in both
small and very large fragment lengths of good performing
markers.
The low genotyping efficiency and poor reproducibility of
the genotype data generated with the present protocols
suggest that archived serum samples will be a problematic
source of DNA for large-scale GWAS [20]. To successfully
locate causative variants in the genome, high genotyping
efficiency and call rates are required from the initial
whole-genome screen. Genotyping error also reduces sta-
tistical power in case control studies [21-23]. The CRLMM
algorithm proved superior to Birdseed in improving the
call rate (663320 +/- 134762 called markers) and repro-
ducibility between technical replicates (>99% concord-
ance between technical replicates) at the expense of very
low genotyping efficiency (6/45 samples passing confi-
dence criteria). The CRLMM confidence measure gave a
useful assessment of chip quality which was readily veri-
fied by inspection of the global genotype clustering.
CRLMM, therefore, is currently the optimum genotype
calling algorithm for the SNP 6.0 array available to most
investigators. CRLMM has been previously shown to pro-
vide more accurate genotype calls and lower drop rates
compared to other Affymetrix default algorithms
(BRLMM and Birdseed) when using large datasets from
non-amplified genomic DNA[18]. Our data validate and
extend this finding to WGA DNA from serum samples.
Genotyping algorithms apply different methods for trans-
forming raw intensity signals from chip arrays to genotype
calls. The good performance of CRLMM can be explained
by the robustness of its confidence metric which appears
to better reflect call accuracy relative to other genotyping
algorithms. Furthermore, CRLMM not only allows meas-
urements of call accuracy but also of chip quality. How-
ever, the improvement in reproducibility of WGA
technical replicates has to be evaluated cautiously. Both
Birdseedv2.0 and CRLMM produced genotypes that had
poor concordance between WGA serum DNA samples
and their corresponding non-amplified genomic DNA. In
contrast to previous and more limited studies with tar-
geted custom genotyping panels, our extensive survey of
archived serum samples and our use of paired serum/
genomic samples clearly demonstrated poor genotyping
performance of WGA samples on the SNP6.0 platform.
Nevertheless, our study showed that approximately 300K
genotypes could be reproducibly retrieved from 20-year
old sera. This suggests that with further improvements in
the laboratory protocols, serum could serve as a reliable,
alternative DNA source for genetic studies. Other genome-
wide genotyping platforms can be explored for genotyp-
ing suboptimal samples such as serum DNA. Of these
platforms, the Illumina Infinium II assay offers compara-
ble marker density as the SNP6.0 platform[24]. Illumina
Infinium II utilizes the bead technology wherein each
bead contains locus specific probes, and allelic discrimi-
nation occurs through single-base primer extension reac-
tions. In addition, several genotype-calling algorithms
were developed for specific application to the Illumina
assays such as GenCall[25], GenoSNP[26] and Illumi-
nus[27]. There is a possibility of improving call rates, call
accuracy and reproducibility because these platforms uti-
lize different chemistries and genotype-calling algorithms.
Conclusions
Archived serum samples may be useful in cases where few
putative causal variants have to be replicated in an inde-
pendent set of samples. In this study, we showed that pro-
cedures could be applied to maximize the quality of
genotype information from WGA DNA from serum sam-
ples. We have proposed to eliminate poor quality samples
in downstream data analysis by imposing QC measuresBMC Genetics 2009, 10:85 http://www.biomedcentral.com/1471-2156/10/85
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based on chip quality analysis. We have also shown that
genotyping algorithms such as CRLMM could better ana-
lyze genotype data from less-optimal DNA source. More-
over, analysis can be limited to genotypes with high
confidence values to improve data quality. However, fur-
ther investigation is still necessary to determine the appro-
priate criteria needed to identify poor quality samples
before the genotyping stage. It is not impossible though,
that marked improvement in WGA and/or genotyping
platform technologies may boost the reliability of serum
as an alternative, cost-effective DNA source for future
association studies.
Methods
Sample description
DNA was purified from 40 anonymized archived sera of
participants from 3 pooled influenza vaccine clinical trials
performed from 1981-1986 at Baylor College of Medi-
cine, Houston, TX. Samples were selected from 695 indi-
viduals and were categorized as high-responders and low-
responders based on rise in antibody responses before
and after immunization. As controls, additional DNA
samples were obtained from peripheral whole blood and
serum samples of 5 adult volunteer donors. Informed
consent was obtained from these participants. This proto-
col was approved by Baylor College of Medicine's Institu-
tional Review Board (IRB).
DNA purification from peripheral whole blood samples
Peripheral whole blood samples were collected in 10 mL
citrate dextran (ACD), yellow top BD vacutainer blood
tubes (VWR International, PA). Samples were kept at
room temperature and processed within 3 days after col-
lection. Purification of genomic DNA from peripheral
whole blood was carried out using Gentra Puregene Blood
Kit (Qiagen, CA) according to manufacturer's protocol.
DNA quantity and A260/A280 ratios were measured using
Nanodrop-ND-1000 spectrophotometer (NanoDrop
Technologies, Inc, DE). Purified genomic DNA were
stored at 4°C until ready for use.
Preparation of whole-genome amplified DNA from serum
Peripheral whole blood samples were collected in 5 mL
BD Vacutainer red top tubes (VWR International, PA).
Fractionation of serum was carried out by allowing blood
samples to clot for 30-60 minutes at room temperature
followed by centrifugation at 2000 rpm for 10 minutes.
Serum supernatant was removed and stored in 500 uL
aliquots at -80°C. Purification of genomic DNA from
serum samples was carried out using QIAamp DNA Blood
Mini Kit (Qiagen, CA). About 500 uL serum was incu-
bated with Qiagen protease and equal volumes of buffer
AL at 56°C for 1 hour and then loaded into QIAamp spin
column. Genomic DNA was washed, dried and eluted
with 20 uL buffer TE. Genomic DNA was quantified using
Nanodrop ND-1000 (NanoDrop Technologies, Inc, DE).
For whole-genome amplification of purified serum DNA,
Repli-g Midi kit (Qiagen, CA) was used according to the
manufacturer's instructions in the user-developed proto-
col for serum and plasma samples. For positive control,
10 ng human genomic DNA were used in every run.
Briefly, 5 μL of purified serum DNA underwent denatura-
tion step by incubating with equal volume of reconsti-
tuted buffer DLB on ice for 10 minutes. The reaction was
neutralized by adding 10 μL of reconstituted stop solu-
tion. Whole genome amplifications were carried out using
thermocycler (PTC-225, MJ Research Inc, MA) by incubat-
ing 30 μL DNA solution with ϕ29 DNA polmerase in 40
uL master mix, as provided by the manufacturer, at 30°C
for 16 hours followed by enzyme inactivation at 65°C for
3 minutes. WGA serum DNA were quantified using Nan-
odrop ND-1000 (NanoDrop Technologies, Inc, DE).
Samples were frozen at -20°C and genotyped within 3
weeks of whole genome amplification.
Quality Control for WGA serum DNA samples
Starting DNA material from archived serum samples must
not be highly degraded to ensure successful application in
WGA and GenomeWide Human SNP Array 6.0. QC met-
rics were imposed at different stages of DNA preparation
so that only samples with acceptable DNA quality were
allowed to reach the genotyping process. Whole-genome
amplification was restricted to purified DNA samples with
yield ≥90 ng. Samples for whole-genome genotyping were
required to have WGA yield of ≥40 ug. Samples, which
passed the QC thresholds for yield, were further tested for
DNA quality. To assess purity of WGA serum DNA sam-
ples, A260/280 ratios were measured using Nanodrop
ND-1000 (NanoDrop Technologies, Inc, DE). The extent
of DNA degradation was initially assessed in WGA serum
DNA samples by carrying out 60 bp fragment amplifica-
tion by PCR. Furthermore, WGA serum DNA samples
were run on 1% agarose gel to detect the presence of a
heavy band around the 10 kb region representing non-
fragmented serum DNA. Samples with good DNA quality
have A260/280 ratio>1.80, 10 kb band on 1% agarose gel
and positive 60 bp fragment amplification by PCR. All
genotyped samples passed all yield and quality QC
requirements.
Whole-genome genotyping
Genotyping was performed on replicate samples from the
same DNA preparation using Genome-Wide Human SNP
Array 6.0 Platform (Affymetrix, CA). The recommended
protocol was followed as described in Affymetrix manual
http://www.affymetrix.com/support/downloads/manu
als/snp6_atp_userguide.pdf. Briefly, all DNA samples
were normalized to 50 ng/μL. Two 5 _L (250 ng) aliquots
were made from each DNA sample followed by digestion
with either NspI or StyI restriction enzymes. Biotin-labe-BMC Genetics 2009, 10:85 http://www.biomedcentral.com/1471-2156/10/85
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ling primer amplification assay was performed on the
resulting DNA fragments in each aliquot. The amplified
products were fragmented, combined and purified using
polystyrene beads. Samples were injected into the car-
tridges housing the oligonucleotide arrays, hybridized,
washed and stained. The washing and staining procedures
were run on Affymetrix fluidics station 450. Mapping
array images were obtain by scanning with GeneChip
Scanner 3000 7G (Affymetrix, CA). CEL files containing
raw signal intensities were stored and used for down-
stream analysis of WGA serum DNA performance on
Genome-Wide Human SNP Array 6.0 Platform (Affyme-
trix, CA) as described below.
Data Analysis Scheme
Datasets
A total of 100 CEL files were generated from 50 sample
replicates, which consisted of 40 WGA-DNA from
archived serum samples and 5 WGA-DNA from serum
samples paired with 5 genomic DNA from peripheral
blood. WGA serum DNA and whole blood genomic DNA
CEL files were clustered separately during genotype calling
as recommended in Affymetrix user-developed protocol
for genotyping WGA-DNA samples. Cluster files for WGA
serum DNA consisted of 89 CEL files. CEL files from 270
HapMap samples were obtained from Affymetrix and
were used to cluster with whole blood genomic DNA CEL
files to improve the accuracy of genotype calls.
Inference of Genotype Calls
Genotype calls were inferred using two recently available,
SNP6.0-compatible algorithms based on raw intensity sig-
nals stored in CEL files: (1) Birdseedv2.0 [17,28] and (2)
CRLMM (Corrected Robust Linear Model with Maximum
Likelihood Classification) [29,30]. The algorithms
selected for genotype calling differ in methods for estimat-
ing the boundaries of each genotype clusters and for
assigning genotype calls. Birdseedv2.0 was implemented
using the Affymetrix, CA Power Tool version 1.8.5 (apt-
1.8.5) as supported in Affymetrix, CA website http://
www.affymetrix.com/support/developer/powertools/
apt_archive.affx. For genotype calling, Birdseedv2.0 pre-
processed the probe signal intensities across all chips
based on BRLMM[31,32]. Expectation Maximization
(EM) algorithm was used to fit a Gaussian mixture models
in 2-dimensional signal A and signal B space. A pseudo-
Bayesian approach was applied to ensure that the bound-
aries derived for each genotype cluster are very close to the
supplied SNP-models. Output genotype calls were coded
as 0, 1, 2, and -1 for AA, AB, BB and no signal, respectively.
Confidence measures were reported as a measure of cer-
tainty genotype prediction based on the fitted models for
each genotype. For genotype calling using CRLMM algo-
rithm, Oligo package v1.2.2 was downloaded (Personal
Communication, Benilton Carvalho) and run in R statis-
tical software (v2.6.1). Raw signal intensities for each
probe were normalized similar to Robust Multi-array
Average (RMA) after correction of sequence and fragment
length effects on log intensities. To further enhance the
precision of genotype inference, gender information for
each sample was supplied as a covariate in a separate phe-
noData object. Log normalized intensities for SNP alleles
were recorded and used to estimate the genotype regions,
which served as a basis for classifying genotype calls. A
likelihood based distance function was applied to esti-
mate the genotype calls and corresponding confidence
values. Genotypes in the output matrix were coded as 1, 2,
3 to represent AA, AB, BB calls, respectively. A separate
matrix containing confidence values were reported to give
an estimate of certainty for each given call. Genotype calls
using Birdseedv2.0 and CRLMM were inferred at the
default confidence thresholds of 0.1 and 0.999, respec-
tively.
Performance Analysis
Output files were uploaded to R statistical software pack-
age (v2.6.1). Per-sample %call rates and concordance
between replicate or paired DNA samples were calculated
to measure the performance of genotyped samples. The
quality of genotyped sample was measured by the extent
of genotype call dropouts. Call rate is defined as the
number of SNPs with successfully called genotype out of
total number of assayed SNP markers. Robustness and
repeatability of genotype calls were measured by concord-
ance between replicate and paired samples. Concordance
is defined as the number of SNPs with consistent calls
between replicate or paired samples. Blood genomic DNA
was set as the gold standard for determining the accuracy
of calls derived from WGA serum DNA samples. Perform-
ances of CRLMM and Birdseedv2.0 genotype calling algo-
rithms when using WGA serum DNA were determined by
comparing percent call rates and concordance results. An
optimum genotype calling algorithm for WGA serum
DNA sample should be able to distinguish good perform-
ing and bad performing samples while maximizing call
rates and concordance between paired and replicate sam-
ples.
Reproducibility
Inconsistencies in calls between replicate samples may
result from errors in whole genome amplification process
due to allele bias amplification or inaccurate definition of
genotype clusters during genotyping. Genotype calls from
Birdseedv2.0 were uploaded in R and Microsoft Access.
SNPs with discordant calls between replicate WGA serum
DNA samples were tallied. Of the total discordant calls,
the proportion of SNPs with heterozygote dropout (AB-
>AA or BB) or allele switch (AA->BB) conversion were
recorded and compared. If discordance between replicate
samples were random, equal occurrence of heterozygote
to homozygote conversion and allele 1 homozygote to
allele 2 homozygote conversion between replicate sam-BMC Genetics 2009, 10:85 http://www.biomedcentral.com/1471-2156/10/85
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ples should be expected. Marked increase in heterozygote
to homozygote conversion may suggest allele bias ampli-
fication during whole-genome amplification of serum
DNA. On the other hand, increased frequency of allele 1
homozygote to allele 2 homozygote calls may reflect
errors in defining genotype clusters during genotype call-
ing.
Relationship of Fragment Length and Reproducibility to SNP 
Performance
Performance of individual SNPs may be affected by the
extent of degradation in the starting serum DNA or diffi-
culty in amplification of large DNA fragment during
whole genome amplification process. Effect of varying
fragment lengths on SNP performance was evaluated.
Information on NspI or StyI fragment size associated with
the assayed SNP was extracted from Genome-Wide
Human SNP Array 6.0 annotation. Using Birdseedv2.0
output files, SNP performance was measured by calculat-
ing the average confidence values for each SNP across all
genotyped WGA serum DNA samples. SNPs with low
average confidence values are poor performers whereas
SNPs with consistently high confidence values are good
performers. SNP performance was also measured by cal-
culating genotype concordance between technical repli-
cates. SNPs with low average concordance rates are poor
performers whereas SNPs with consistently high average
concordance rates are good performers. Linear regression
was performed on average confidence values against frag-
ment size using R statistical software. The relationship
between repeatability of genotype calls between replicate
samples and SNP performance was also evaluated. Linear
regression was performed on average confidence values
against concordance between replicate samples to identify
correlation using R statistical software.
Assessment of Signal Quality
Dropouts in calls or inconsistencies between replicates
calls may result from non-distinct separation of clusters
for each genotype. Quality of signal intensities for good
and bad performing WGA serum DNA samples was visu-
ally examined. Normalized log signal intensities for probe
A (θA ) and probe B(θB ) for each SNP were extracted from
CRLMM output files using R statistical package software
(v2.6.1)[30]. Geneplotter package was used to generate
2D density plots of θB against signal θA . Signal to noise
ratio was assessed by examining the stratification of esti-
mated regions for homozygous and heterozygous geno-
type calls. Good quality samples were expected to display
distinct boundaries for each genotype cluster.
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